宣痹调气汤治疗类风湿关节炎气血两虚证临床观察

Xuanbi Tiaoqi Decoction in Treating Rheumatoid Arthritis of Deficiency of Qi and Blood Syndrome

目的探讨宣痹调气汤治疗类风湿关节炎(RA)气血两虚证的效果和安全性。方法将80例RA气血两虚证患者随机分为观察组和对照组,每组40例。对照组予常规西药治疗,观察组在对照组基础上加用宣痹调气汤治疗,疗程均为8周。比较两组临床疗效、中医证候积分、主要症状和体征情况、实验室指标、塞来昔布用药情况和不良反应发生情况。结果观察组临床总有效率为97.37%(37/38),显著高于对照组的76.32%(29/38)(P<0.05)。治疗后,观察组中医证候积分、关节肿胀数、关节压痛数、晨僵时间、视觉模拟量表(VAS)评分、28个关节的疾病活动度评分(DAS28)、红细胞沉降率(ESR)水平、血小板(PLT)水平、C反应蛋白(CRP)水平、塞来昔布用药频次和剂量均显著低于对照组(P<0.05)。观察组不良反应发生率为5.26%(2/38),显著低于对照组的21.05%(8/38)(P<0.05)。结论宣痹调气汤是治疗RA气血两虚证安全有效的方法,具有深入研究的价值。

Objective To explore the efficacy and safety of Xuanbi Tiaoqi decoction in treating rheumatoid arthritis(RA)of deficiency of qi and blood syndrome.Methods A total of 80 patients with RA of deficiency of qi and blood syndrome were randomly divided into observation group and control group,with 40 patients in each group.The control group was treated with methotrexate tablets,elamod tablets,folic acid tablets and celecoxib tablets.The observation group was treated with Xuanbi Tiaoqi decoction on the basis of the con-trol group,with a course of 8 weeks.The clinical efficacy,TCM syndrome score,main symptoms and signs,laboratory indexes,cele-coxib administration and adverse reactions were compared between the two groups.Results The total clinical effective rate of the ob-servation group was 97.37%(37/38),which was significantly higher than that of the control group(76.32%,29/38)(P<0.05).After treat-ment,TCM syndrome score,joint swelling number,joint tenderness number,morning stiffness time,visual analog scale(VAS)score,disease activity score of 28 joints(DAS28),erythrocyte sedimentation rate(ESR)level,platelet(PLT)level,C-reactive protein(CRP)level,celeoxib administration frequency and dose in observation group were significantly lower those of control group(P<0.05).The in-cidence of adverse reactions in the observation group was 5.26%(2/38),which was significantly lower than that in the control group(21.05%,8/38)(P<0.05).Conclusion Xuanbi Tiaoqi decoction is a safe and effective strategy for treating RA of deficiency of qi and blood syndrome,and has the value of in-depth research.